P

Inventor

BHANDARI ASHOK

US30 patents
⚠️ This page may combine multiple inventors who share the name “BHANDARI ASHOK”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

PROTAGONIST THERAPEUTICS INC

24 patents
US9518091B2Dec 13, 2016

A4B7 peptide monomer and dimer antagonists

PROTAGONIST THERAPEUTICS INC34 citations98
US9624268B2Apr 18, 2017

Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

PROTAGONIST THERAPEUTICS INC40 citations97
US10941183B2Mar 9, 2021

Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

PROTAGONIST THERAPEUTICS INC13 citations94
US10626146B2Apr 21, 2020

α4β7 thioether peptide dimer antagonists

PROTAGONIST THERAPEUTICS INC15 citations94
US10278957B2May 7, 2019

Opioid agonist peptides and uses thereof

PROTAGONIST THERAPEUTICS INC16 citations94
US10059744B2Aug 28, 2018

α4β7 thioether peptide dimer antagonists

PROTAGONIST THERAPEUTICS INC22 citations94
US9809623B2Nov 7, 2017

α4β7 peptide monomer and dimer antagonists

PROTAGONIST THERAPEUTICS INC26 citations94
US9714270B2Jul 25, 2017

a4B7 integrin thioether peptide antagonists

PROTAGONIST THERAPEUTICS INC27 citations94
US9273093B2Mar 1, 2016

α4β7 peptide dimer antagonists

PROTAGONIST THERAPEUTICS INC31 citations94
US10196424B2Feb 5, 2019

Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

PROTAGONIST THERAPEUTICS INC26 citations93
US10035824B2Jul 31, 2018

Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

PROTAGONIST THERAPEUTICS INC24 citations93
US10023614B2Jul 17, 2018

Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

PROTAGONIST THERAPEUTICS INC23 citations93
US11111272B2Sep 7, 2021

α4α7 peptide monomer and dimer antagonists

PROTAGONIST THERAPEUTICS INC10 citations86
US10787490B2Sep 29, 2020

Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

PROTAGONIST THERAPEUTICS INC18 citations85
US10301371B2May 28, 2019

Cyclic monomer and dimer peptides having integrin antagonist activity

PROTAGONIST THERAPEUTICS INC19 citations85
US10729676B2Aug 4, 2020

Opioid agonist peptides and uses thereof

PROTAGONIST THERAPEUTICS INC10 citations83
US11041000B2Jun 22, 2021

Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

PROTAGONIST THERAPEUTICS INC13 citations82
US10407468B2Sep 10, 2019

Methods for synthesizing α4β7 peptide antagonists

PROTAGONIST THERAPEUTICS INC13 citations82
US11840581B2Dec 12, 2023

α4β7 thioether peptide dimer antagonists

PROTAGONIST THERAPEUTICS INC1 citations73
US11472842B2Oct 18, 2022

Analogues of hepcidin mimetics with improved in vivo half lives

PROTAGONIST THERAPEUTICS INC5 citations72
US11753443B2Sep 12, 2023

Conjugated hepcidin mimetics

PROTAGONIST THERAPEUTICS INC3 citations70
US11884748B2Jan 30, 2024

Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

PROTAGONIST THERAPEUTICS INC0 citations62
US12552836B2Feb 17, 2026

Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

PROTAGONIST THERAPEUTICS INC0 citations59
US12234300B2Feb 25, 2025

Conjugated hepcidin mimetics

PROTAGONIST THERAPEUTICS INC0 citations59

JANSSEN BIOTECH INC

3 patents

JANSSEN PHARMACEUTICA NV

1 patent

HOLMES CHRISTOPHER P

1 patent

SMITHKLINE BEECHAM CORP

1 patent